ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves

AngioDynamics (ANGO) reported a stronger-than-expected Q1 FY26, with a pro-forma adjusted loss per share of 10 cents, surpassing estimates, and revenues rising 12.2% to $75.7 million, largely driven by a 26.1% increase in its Med Tech segment and a 90 basis point expansion in gross margin. This performance led the company to raise its full-year FY26 net sales guidance to $308-$313 million and narrow its adjusted loss per share outlook, reflecting management's confidence in continued growth, particularly from its key Med Tech platforms.

Analysis

AngioDynamics, Inc. (ANGO) reported a robust start to fiscal 2026, with Q1 pro-forma revenues growing 12.2% year-over-year to $75.7 million, exceeding consensus estimates by 4.8%. The performance was driven by the high-growth Med Tech segment, which expanded 26.1% and now constitutes nearly half of total sales, contrasting with the Med Device segment's modest 2.3% growth. Key Med Tech platforms showed significant momentum, with Mechanical Thrombectomy sales up 41.2% and NanoKnife sales increasing 26.7%. This favorable revenue mix, combined with operational efficiencies, contributed to a 90 basis point expansion in pro-forma gross margin to 55.3% and a narrower adjusted loss per share of 10 cents, which beat estimates. In a sign of confidence, management raised the full-year revenue guidance to $308-$313 million and increased the Med Tech growth forecast to 14-16%. While the company maintains a debt-free balance sheet, cash and cash equivalents declined to $38.8 million from $55.9 million, reflecting a cash burn from operations of $15.9 million for the quarter. The stock's 27.5% year-to-date gain, sharply outperforming the industry's 8.7% decline, reflects market approval of this strategic execution.

Key Decisions for Investors

• The strong Q1 results validate ANGO's strategic pivot to its high-growth Med Tech segment, and investors should continue to focus on this segment's growth rate as the primary performance indicator.
• Monitor the adoption rate and revenue contribution of the NanoKnife platform, as the new CPT I reimbursement code effective January 1, 2026, represents a significant potential catalyst for accelerated growth and margin improvement.
• Given the operational cash use of $15.9 million in the quarter, it is critical to track the company's cash burn rate and its progress toward profitability, especially as it continues to invest in sales and marketing.
• Investors should weigh the raised full-year guidance and positive momentum against the noted $4-$6 million headwind from tariffs and the stock's significant outperformance year-to-date when assessing entry points or position sizing.